HFSA ePoster Library

Survival Benefit Observed In Patients With Mayo Stage IV AL Amyloidosis Following Birtamimab Supports Initiation Of Confirmatory AFFIRM-AL Phase 3 Study
HFSA ePoster Library. Gertz M. 09/10/21; 343869; LBCT-011
Morie Gertz
Morie Gertz
Login now to access Regular content available to all registered users.
Discussion Forum (0)
Code of conduct/disclaimer available in General Terms & Conditions

What's new

HFSA Releases Scientific Statement on the Intersection of COVID-19 and Heart Failure

About Us

The Heart Failure Society of America is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, and patients. Look below for more information about the society.
2025 ©
Heart Failure Society of America
USER TERMS AND CONDITIONS / PRIVACY POLICY
(Amended according to GDPR)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies